Rethinking Cat Allergen Management: From Fel d 1–8 to the Shared Home

8

WHO/IUIS-named domestic-cat allergens1

up to 96%

reported share of cat sensitization involving Fel d 12

20–24 weeks

only 8 of 15 homes reached control-like levels after cat removal4

−47%

mean active Fel d 1 change on hair at Week 10 in a published IgY study7

EXECUTIVE BRIEF

Four conclusions before the product discussion

Visible hair is not a reliable exposure proxy

Cat allergens can remain airborne on small particles and travel on clothing into places where no cat lives. What can be seen is only part of the system.

A single intervention faces a continuous loop

Source, coat, textiles, air and repeated contact form an ongoing cycle. Even after source removal, household Fel d 1 can take months to decline.

Evidence must be read by endpoint

A reduction in measured active allergen and an improvement in human symptoms are different conclusions. Feline endpoints are established more strongly than controlled human outcomes.

The category moat is an evidence system

The hard-to-copy asset is not seven products in one portfolio; it is a defined role, common assay language, observable cadence and staged evidence path for every SKU.

METHODOLOGY

01Evidence scope

WHO/IUIS database, practice parameters, consensus documents, systematic reviews and peer-reviewed primary studies

02Priority rule

Study design and endpoint first, direction and effect size second; publication count is not a proxy for quality

03Comparison rule

Analytical, environmental-exposure and human clinical endpoints are assessed separately

04Boundary

A targeted evidence synthesis for product and category design—not a registration-grade systematic review or medical advice

REFRAMING THE PROBLEM

Cat allergens operate as a continuously replenished exposure loop—not a pile of hair that can be removed once

Most cat-allergic people are not reacting primarily to the hair fibre itself. Hair functions as logistics: grooming transfers proteins from saliva and sebaceous sources to the coat; hair, dander and particles of different sizes then carry them into air, textiles and furniture. The management target is therefore not “hair count,” but a system of continuous production, transfer, deposition and resuspension.

01Production

Salivary and sebaceous sources produce Fel d 1 and other proteins

→

02Transfer

Grooming moves proteins onto the coat and dander

→

03Deposition

Particles enter air, bedding, sofas and clothing

↺

04Re-exposure

Contact and disturbance return deposits to the breathing zone

EXHIBIT 1

Fel d 1 exists on both larger particles and fine particles that may remain airborne

Particle-size distribution in air samples from nine cat-owning homes

75%25%

≥5 μm larger particles≤2.5 μm fine particles

Source: Luczynska et al., 1990. The fine-particle share ranged from 10% to 62% across homes; the exhibit shows the aggregate distribution.3

20–24 weeks

Source removal does not produce an immediate reset

In a longitudinal study of 15 homes, only eight reached levels comparable with cat-free controls after 20–24 weeks; decline was slower in the remaining homes.4

Cross-space

Clothing extends exposure beyond the home

School studies showed cat allergen being transported on clothing from cat-owning homes into classrooms and then acting as an indirect exposure source.5

98%

“No cat” does not mean “no Fel d 1”

Fel d 1 was detected in 98% of 405 German homes; 28% of never-cat homes exceeded 2 μg/g dust.22

Measurement matters as much as removal. Settled dust and airborne exposure are different endpoints: molecular-allergy literature cautions that settled-dust concentration should not be used as a direct surrogate for airborne exposure, while a single universal symptom threshold can obscure individual sensitivity, particle distribution and contact duration.14 13

KEY TAKEAWAY

Visible hair represents only one layer. Floor cleaning alone leaves the continuously replenished source, the coat, textile reservoirs and inhalable particles largely unaddressed.

MOLECULAR PORTFOLIO

Fel d 1 matters most—but “most important” does not mean “only one”

WHO/IUIS lists Fel d 1–8 as eight distinct domestic-cat allergen components. Fel d 1 is the best-studied anchor and has been associated with up to 96% of sensitization to cats in the literature. Yet molecular profiles vary. In a 2023 component-resolved cohort, positivity was 91.7% for Fel d 1 and 41% for Fel d 4. Fel d 2, Fel d 4 and Fel d 7 also carry distinct cross-species implications, so positivity to cat extract alone does not fully describe a person's molecular sensitization profile.2 1014

EXHIBIT 2

Fel d 1–8 differ not only by molecular name, but also by source, sensitization frequency and cross-reactivity

Synthesis of WHO/IUIS and molecular-diagnosis literature; frequencies from heterogeneous cohorts are not directly additive

ComponentProtein familyPrimary sourceReported signalWhy it matters

Fel d 1

Secretoglobin

Saliva · dander · skin

>90%

Core marker of genuine cat sensitization; deepest evidence base

Fel d 2

Serum albumin

Dander · serum · urine

14–30%

Cross-reacts with porcine, canine and equine albumins; linked to cat–pork syndrome

Fel d 3

Cystatin-A

Dander

≈10%

Limited population evidence; not a routine commercial diagnostic component

Fel d 4

Lipocalin

Saliva

≤63%

Important non-Fel d 1 component; cross-reactivity with Can f 6 and Equ c 1

Fel d 5

Immunoglobulin A

Saliva · serum

heterogeneous

Carries α-Gal epitopes; IgE recognition does not necessarily equal clinical relevance

Fel d 6

Immunoglobulin M

Saliva · serum

limited

Shares α-Gal-related analytical complexity with Fel d 5

Fel d 7

Lipocalin

Saliva

≈40%

Cross-reacts with canine Can f 1; some sensitized people lack detectable Fel d 1 IgE

Fel d 8

Latherin-like protein

Saliva

≈20%

Often absent from natural dander extracts; clinical evidence remains limited

Sources: WHO/IUIS; Popescu & Ganea, 2021. Ranges come from populations that differ by geography, age and diagnostic method; they do not imply equal target weighting or predict individual severity.1 14

The OKCLEAR research logic

Fel d 1 is the highest-priority anchor with the deepest public evidence. Fel d 1–8 is the broader R&D map. “Coverage” refers to target selection, antigen design, analytical methods and patent strategy—not an assumption that all eight components carry equal clinical weight. A disciplined portfolio ranks targets by population frequency × clinical relevance × measurability × intervention feasibility before assigning primary and secondary targets to a SKU.

EVIDENCE AUDIT

How far has the published IgY evidence progressed?

IgY is an egg-derived immunoglobulin. The specific anti-Fel d 1 IgY approach is designed to bind Fel d 1 after the cat produces it, thereby reducing immunologically active Fel d 1 detected by the analytical method. It does not edit the cat's genes or stop all Fel d 1 production.

EXHIBIT 3

Published IgY research shows why response distribution matters alongside the mean

105 cats; two-week baseline plus ten-week intervention; active Fel d 1 on hair measured by ELISA

86%

of cats achieved at least a 30% reduction in active Fel d 1 on hair

50%

of cats achieved at least a 50% reduction in active Fel d 1 on hair

47%

mean reduction by Week 10

When did it begin?

A significant mean reduction was observed from Week 3. By Week 10, the mean was 47%, with individual reductions of approximately 33%–71%.

What does it show?

It shows that an anti-Fel d 1 IgY dietary route can change measured active Fel d 1 on the cat's coat.

What cannot be inferred?

It cannot automatically be extrapolated to different formulations or doses, or equated with symptom improvement in every person.

Source: Satyaraj et al., 2019. The study was funded by Nestlé Purina Research.7

Evidence is a ladder—not an effective/ineffective switch

Mechanistic evidence

IgY–Fel d 1 binding and inhibition of IgE binding

Feline biological endpoints

Active Fel d 1 in saliva and on hair

Feline safety

Adult-cat studies and 27 kittens followed for 84 days

Human real-world signal

Open-label MASK-air® proof-of-concept

Next evidence threshold

Randomized, blinded, controlled and SKU-specific validation

A kitten study adds a separate safety endpoint. Twenty-seven eight-week-old kittens were randomized to diets containing 0, 8 or 16 ppm AFD1 and followed for 84 days. No nutritional deficiency, clinical adverse event or biologically significant hematology difference was reported. This supports tolerability of the studied formulations; it does not answer the human symptom question.2

EXHIBIT 4

A home-based human proof-of-concept produced a positive signal—but not confirmatory evidence

Share of well-controlled days recorded through MASK-air®

**36%**Baseline

**65%**Month 1

**77%**Month 2

**86%**Month 3

How to read this exhibit

The study enrolled 49 adults living with cats and diagnosed with cat allergy by specialists. All switched to the same commercial anti-Fel d 1 IgY diet and recorded symptoms and medication in an app. There was no placebo or parallel control and follow-up data were incomplete; the result is therefore hypothesis-generating rather than confirmatory.

Source: Bousquet et al., 2024. Well-controlled days increased from 36% at baseline to 86% at Month 3; the authors explicitly describe the study as an open-label proof-of-concept.9

EXHIBIT 5

The word “reduction” carries different weight depending on study design

Audit of pivotal studies by sample, design, endpoint, result and limitation

QuestionSample & durationDesign / endpointPrimary readoutBoundary

Coat IgY

105 cats; 2-week baseline + 10-week intervention

Single-arm longitudinal; ELISA

Mean active Fel d 1 reduction of 47% by Week 107

No parallel control; industry-funded; not a human endpoint

Kitten safety

27 eight-week-old kittens; 84 days

Randomized 0 / 8 / 16 ppm groups

No reported nutritional deficiency, clinical adverse event or biologically significant hematology difference2

Addresses tolerability of studied diets—not allergen or human symptom efficacy

Human home signal

49 cat-allergic adults living with cats; 3 months

Open-label, single-arm; MASK-air®

Well-controlled days rose from 36% to 86%9

No placebo or parallel control; incomplete follow-up

HEPA clinical control

35 cat-allergic people living with cats; 3 months

Double-blind, placebo-controlled

Airborne Fel d 1 fell, but symptoms, lung function and medication did not differ15

Small trial; tests a combined environmental package, not a product

Interpretation: public evidence supports the mechanism, feline active-Fel d 1 endpoints and safety of studied formulations; stronger randomized human evidence remains necessary.

EXHIBIT 6

A scientific claim must cross four endpoints; it cannot jump from assay to human outcome

Each step to the right requires more subjects, controls and investment

Analytical endpoint

Active/total Fel d 1, method and matrix

Does the target measure change in the sampled material?

→

Exposure endpoint

Coat, air, textile and hard surfaces

Does load change along a real contact pathway?

→

Human observational endpoint

Symptoms, medication, controlled days

Does a consistent directional signal emerge during use?

→

Confirmatory clinical endpoint

Randomization, blinding, control and prespecified statistics

Can the change be attributed to the intervention?

IMPORTANT BOUNDARY

“Change in a target-allergen indicator” is a valid analytical conclusion, but not a human efficacy conclusion. Public materials, the website and test reports should use the same endpoint language so analytical indicators are not misread as human symptom improvement.

SYSTEM DESIGN

Why OKCLEAR is building a source–coat–home system rather than another cleaning spray

The data point to a clear design principle: the exposure chain has multiple nodes and keeps cycling. Dietary routes address active-allergen indicators on the cat; washing and wiping address the coat surface; environmental products address textiles, contact surfaces and the litter-box area. These roles are complementary rather than interchangeable.

EXHIBIT 7

No single intervention covers source, coat, air, reservoirs and human outcomes

Direction of evidence, limitations and a rational role in the portfolio

RouteNodeObserved evidenceKey limitation

Cat removal****Source

After 20–24 weeks, only 8 of 15 homes reached cat-free control levels4 18

Clear environmental logic; high practical and emotional cost

Cat washing****Coat

Small studies observed short-term airborne Fel d 1 reductions of 44%–79%6

The effect did not reliably persist to the next weekly wash

HEPA air filtration****Air

A 22-bedroom study reported a median Fel d 1 reduction of 76.6%16 15

A 35-person blinded trial lowered airborne allergen without changing disease activity

HEPA vacuuming****Dust / surfaces

Modern devices can limit leakage, but cleaning disturbs deposited material19

Personal inhaled exposure rose roughly 3–5-fold during vacuuming in five homes

Anti-Fel d 1 IgY diet****Source / coat

Mean active Fel d 1 on hair fell 47% at Week 10 in 105 cats7 9

Feline evidence is more developed; human evidence remains mainly open-label

Medication / AIT****Human symptoms

Selected by clinicians according to diagnosis and disease severity18

A medical pathway; it does not remove the household source and is not replaced by pet products

Evidence synthesis: lowering an environmental measure is not synonymous with clinical benefit. The Cochrane review found only two small air-filtration trials totaling 57 participants and could not reach a definitive conclusion.17

LayerProduct setCadenceSuggested validation KPI

Source

Complete baked cat food · Cat Allergen-Reducing Powder

Daily

Active target-allergen indicators in saliva and on the coat

Coat

Cat-allergen care shampoo · Rinse-free cleaning glove

Periodic wash + frequent wipe

Target-allergen load on the coat and in wipe eluates

Home

Cat-allergen care spray (compound bioenzyme technology route) · Cassava cat litter

By touchpoint

Target-allergen indicators on textiles, hard surfaces and around litter

ApproachPrimary coverageStructural blind spotRole in a system

One-off cleaning

Visible hair and selected surfaces

Continuous source and redeposition

Short-term load management

HEPA / air treatment

Part of the airborne fraction

Source, coat and textile reservoirs

Air-layer support

IgY dietary route

Active Fel d 1 indicators on the cat

Existing deposits and other components

Source-layer anchor

OKCLEAR portfolio

Source + coat + home

Requires continuing SKU-level validation

An executable daily pathway

A

Published science

Fel d 1 origin, spread and persistence, plus existing research on the anti-Fel d 1 IgY route.

B

OKCLEAR product logic

A Fel d 1–8 R&D map and seven products distributed across source–coat–home touchpoints.

C

Product-level evidence

“As early as Day 1” refers to target-allergen indicator changes observed under defined OKCLEAR product test conditions. Use conclusions depend on the specific SKU evidence.

EVIDENCE BOUNDARY

From published mechanism to product conclusion, evidence must be read in layers

Published mechanism research, ingredient testing, finished-product testing and human research are different evidence levels. OKCLEAR does not present mechanism or ingredient results as finished-product effects, and it does not infer human symptom improvement without corresponding research.

Product conclusions should remain tied to the applicable SKU, batch, sample, assay, time point and test condition. When reviewing materials, check whether those conditions match the statement being made.

LIVING GUIDE · 22 MIN**You love your cat. Why does home still feel so hard?**Move from lived pain and one-point solution gaps to the OKCLEAR capabilities behind a fuller source–coat–home routine →

GLOBAL PARTNERSHIPS

Partner with us to validate and build the category

We welcome pet brands, importers, distributors, retailers and R&D partners for finished-product distribution, OEM/ODM, regional validation and co-development.

info@okclearpet.com →

FAQ

Frequently asked questions

Is cat hair itself the allergen?

Usually, no. Hair is better understood as a carrier. Proteins such as Fel d 1 can attach to hair, dander and particles before moving into fabrics, furniture and air.

Are Fel d 1–8 eight versions of one protein?

No. WHO/IUIS lists them as eight distinct domestic-cat allergen components with different biochemical identities and molecular masses.

Do published IgY studies prove clinical efficacy for an OKCLEAR product?

No. They support the scientific mechanism and research feasibility of the IgY route. Product conclusions depend on the formulation, dose, analytical method and evidence for the specific SKU.

Why is one cleaning event unlikely to be enough?

Allergens are continuously transferred from the cat to the coat and then into the home. Grooming may reduce short-term load, but published data show that the reduction may not persist until the next week.

Does OKCLEAR work with overseas distributors and brands?

Yes. OKCLEAR welcomes discussions with pet brands, importers, distributors, retailers and product-development partners.

SOURCES

References and market context

Academic sources support the allergen and IgY discussion. Consulting research is used only for pet-consumer context, not as product-efficacy evidence.

1. Peer-reviewed study/databaseWHO/IUIS Allergen Nomenclature — Felis domesticus allergens Fel d 1–8
2. Peer-reviewed study/databaseHedrick et al. Evaluation of anti-Fel d 1 IgY ingredient for pet food on growth performance in kittens. Front Vet Sci. 2024.
3. Peer-reviewed study/databaseLuczynska et al. Airborne concentrations and particle size distribution of Fel d 1. Am Rev Respir Dis. 1990.
4. Peer-reviewed study/databaseWood et al. The effect of cat removal on allergen content in household dust. J Allergy Clin Immunol. 1989.
5. Peer-reviewed study/databaseAlmqvist et al. School as a risk environment and a site for transfer of cat allergen. J Allergy Clin Immunol. 1999.
6. Peer-reviewed study/databaseAvner et al. Evaluation of techniques for washing cats and the effect on airborne Fel d 1. J Allergy Clin Immunol. 1997.
7. Peer-reviewed study/databaseSatyaraj et al. Reduction of active Fel d 1 from cats using an anti-Fel d 1 egg IgY antibody. Immun Inflamm Dis. 2019.
8. Peer-reviewed study/databaseSatyaraj et al. Anti-Fel d 1 IgY-containing egg ingredient lowers allergen levels in cat saliva. J Feline Med Surg. 2019.
9. Peer-reviewed study/databaseBousquet et al. Proof-of-concept study of anti-Fel d 1 IgY antibodies in cat food using MASK-air®. Clin Transl Allergy. 2024.
10. Peer-reviewed study/databaseRoger et al. Component-resolved diagnosis in patients sensitized to cat and dog allergens. 2023.
11. Peer-reviewed study/databaseBonnet et al. An update on molecular cat allergens: Fel d 1 and what else? Allergy Asthma Clin Immunol. 2018.
12. Market contextBoston Consulting Group. Pet Owners Are Changing: How Will the Industry Respond? 2025.
13. Practice parameterPortnoy et al. Environmental assessment and exposure control: a practice parameter—furry animals. Ann Allergy Asthma Immunol. 2012.
14. Peer-reviewed study/databasePopescu & Ganea. Molecular diagnosis in cat allergy. World J Methodol. 2021.
15. Peer-reviewed study/databaseWood et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998.
16. Peer-reviewed study/databaseMaya-Manzano et al. Effect of air filtration on cat and dog allergens and particulate matter in homes. Clin Transl Allergy. 2022.
17. Systematic review/reviewKilburn et al. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev.
18. ConsensusDávila et al. Consensus document on dog and cat allergy. Allergy. 2018.
19. Peer-reviewed study/databaseGore et al. HEPA vacuum cleaners and personal inhaled cat allergen exposure. J Allergy Clin Immunol. 2003.
20. Systematic review/reviewSparkes. Human allergy to cats: impact on cat ownership and allergy management. J Feline Med Surg. 2022.
21. Peer-reviewed study/databaseMatulka et al. Multi-level safety studies of an anti-Fel d 1 IgY ingredient in cats. Front Vet Sci. 2020.
22. Peer-reviewed study/databaseFahlbusch et al. Predictors of cat allergen Fel d 1 in house dust of German homes. J Investig Allergol Clin Immunol. 2002.
23. Peer-reviewed study/databaseGergen et al. Pet allergen exposure and asthma morbidity in the US population. J Allergy Clin Immunol Pract. 2018.